Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Piotroski F-Score: 7 (As of Jul. 03, 2026) — Near Median


NSE:MADHAVBAUG Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
80 GF Score
Price ₹187.00
GF Value ₹228.09
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vaidyane Ayurved Laboratories Piotroski F-Score?

Vaidyane Ayurved Laboratories NSE:MADHAVBAUG +2.05% 80 Piotroski F-Score is 7 as of Jul. 03, 2026, which is at its 10-year median of 7.00. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 80/100 and a GF Value™ of ₹228.09 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, Vaidyane Ayurved Laboratories ranks better than 91.85% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vaidyane Ayurved Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Vaidyane Ayurved Laboratories's Piotroski F-Score or its related term are showing as below:

NSE:MADHAVBAUG' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 7
Current: 7

During the past 8 years, the highest Piotroski F-Score of Vaidyane Ayurved Laboratories was 7. The lowest was 4. And the median was 7.

Vaidyane Ayurved Laboratories  (NSE:MADHAVBAUG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Vaidyane Ayurved Laboratories Piotroski F-Score Related Terms


Vaidyane Ayurved Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Vaidyane Ayurved Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaidyane Ayurved Laboratories Piotroski F-Score Chart

Vaidyane Ayurved Laboratories Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial 7.00 5.00 4.00 6.00 7.00

Vaidyane Ayurved Laboratories Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 6.00 0.00 7.00

NSE:MADHAVBAUG vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaidyane Ayurved Laboratories Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Vaidyane Ayurved Laboratories's Piotroski F-Score falls into.


NSE:MADHAVBAUG
80GF Score
Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹90 Mil.
Cash Flow from Operations was ₹54 Mil.
Revenue was ₹1,069 Mil.
Gross Profit was ₹880 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (767.094 + 1045.072) / 2 = ₹906.083 Mil.
Total Assets at the begining of this year (Mar25) was ₹767 Mil.
Long-Term Debt & Capital Lease Obligation was ₹26 Mil.
Total Current Assets was ₹443 Mil.
Total Current Liabilities was ₹111 Mil.
Net Income was ₹71 Mil.

Revenue was ₹899 Mil.
Gross Profit was ₹709 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (697.142 + 767.094) / 2 = ₹732.118 Mil.
Total Assets at the begining of last year (Mar24) was ₹697 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹303 Mil.
Total Current Liabilities was ₹112 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vaidyane Ayurved Laboratories's current Net Income (TTM) was 90. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vaidyane Ayurved Laboratories's current Cash Flow from Operations (TTM) was 54. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=89.866/767.094
=0.11715122

ROA (Last Year)=Net Income/Total Assets (Mar24)
=71.361/697.142
=0.10236222

Vaidyane Ayurved Laboratories's return on assets of this year was 0.11715122. Vaidyane Ayurved Laboratories's return on assets of last year was 0.10236222. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Vaidyane Ayurved Laboratories's current Net Income (TTM) was 90. Vaidyane Ayurved Laboratories's current Cash Flow from Operations (TTM) was 54. ==> 54 <= 90 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=25.853/906.083
=0.02853271

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/732.118
=0

Vaidyane Ayurved Laboratories's gearing of this year was 0.02853271. Vaidyane Ayurved Laboratories's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=443.096/111.109
=3.98793977

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=302.847/112.245
=2.698089

Vaidyane Ayurved Laboratories's current ratio of this year was 3.98793977. Vaidyane Ayurved Laboratories's current ratio of last year was 2.698089. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Vaidyane Ayurved Laboratories's number of shares in issue this year was 11.177. Vaidyane Ayurved Laboratories's number of shares in issue last year was 12.346. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=879.771/1069.064
=0.82293576

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=708.509/899.229
=0.7879072

Vaidyane Ayurved Laboratories's gross margin of this year was 0.82293576. Vaidyane Ayurved Laboratories's gross margin of last year was 0.7879072. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1069.064/767.094
=1.39365449

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=899.229/697.142
=1.28987925

Vaidyane Ayurved Laboratories's asset turnover of this year was 1.39365449. Vaidyane Ayurved Laboratories's asset turnover of last year was 1.28987925. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vaidyane Ayurved Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Piotroski F-Score of 7 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is near median its historical median of 7.00. Over the past decade, Vaidyane Ayurved Laboratories' Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #80 out of 981 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Vaidyane Ayurved Laboratories' Piotroski F-Score too high?
Vaidyane Ayurved Laboratories' current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Vaidyane Ayurved Laboratories' value of 7 is 40% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #80 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #80 out of 981 companies for Piotroski F-Score. This places Vaidyane Ayurved Laboratories in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Vaidyane Ayurved Laboratories' value of 7 is 40% above this benchmark. Historically, Vaidyane Ayurved Laboratories' own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.09, compared to a current price of ₹187.00 — trading 18% below its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Drug Manufacturers industry median of 5.00. Vaidyane Ayurved Laboratories' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Piotroski F-Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?

Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued. The current stock price of ₹187.00 is trading 18% below its estimated GF Value™ of ₹228.09. GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:MADHAVBAUG:

  • Piotroski F-Score: 7 (near median its 10-year median of 7.00)
  • GF Value™: ₹228.09 vs. price of ₹187.00 (18% below fair value)
  • GF Score™: 80/100 with 4 warning signs
  • Industry Position: 40% above the Drug Manufacturers median (#80 of 981)

No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vaidyane Ayurved Laboratories Business Description

Address 201B, Bhoomi Velocity, Above ICICI Bank, Road No. 23, Wagle Estate, Thane (West), Thane, MH, IND, 400604
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
80GF Score

Get the complete analysis for NSE:MADHAVBAUG

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹187.00
Price
₹228.09
GF Value